Truqap can be a kinase inhibitor that actually works by blocking pathways that help the cancer cells survive and increase, so reduces cancer growth. Truqap is from a category of medicines identified as an AKT inhibitor. Truqap acquired FDA acceptance on November 17, 2023, immediately after construct